Rafael HoldingsRFL
Market Cap: $39.6M
About: Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.
Employees: 13
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
600% more call options, than puts
Call options by funds: $7K | Put options by funds: $1K
1.12% less ownership
Funds ownership: 11.68% [Q1] → 10.56% (-1.12%) [Q2]
7% less funds holding
Funds holding: 45 [Q1] → 42 (-3) [Q2]
24% less capital invested
Capital invested by funds: $4.78M [Q1] → $3.62M (-$1.17M) [Q2]
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for RFL.
Financial journalist opinion
Based on 4 articles about RFL published over the past 30 days